AndreaBozzo/ceres-open-data-index huggingface dataset:
Drug Abuse Warning Network (DAWN-2008)

<p>The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.<br />
DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.<br />
The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year.  Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.This study has 1 Data Set.</p>
Compound 525731: (p-Methylbenzylidene)-pentyl-amine

Chemical compound data from PubChem database. IUPAC Name: 1-(4-methylphenyl)-N-pentylmethanimine. Molecular Formula: C13H19N. Molecular Weight: 189.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530150: Trimethylsilyl acetylsalicylate

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2-acetyloxybenzoate. Molecular Formula: C12H16O4Si. Molecular Weight: 252.34. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399536-T1: [Translated] METHOD FOR PRODUCING PHARMACEUTICAL MULTIPARTICLE PRODUCTS

Chemical patent from PubChem database. Patent Number: AT-E399536-T1. Title: Novel Pharmaceutical Composition. Filing Date: 2005-01-20. Inventors: Wilson, James, Brown, Patricia, Lee, David. Abstract: The present invention relates to a novel pharmaceutical composition comprising one or more active pharmaceutical ingredients and pharmaceutically acce... IPC Classifications: C07C, C07B, A61K. This patent covers 15 claims related to 5 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Compound 526404: 3,9-Dibromo,1,2-dichloro-dibenzo-dioxin

Chemical compound data from PubChem database. IUPAC Name: 3,9-dibromo-1,2-dichlorodibenzo-p-dioxin. Molecular Formula: C12H4Br2Cl2O2. Molecular Weight: 410.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NNDSS - TABLE 1HH. Syphilis, Congenital to Syphilis, Primary and Secondary

NNDSS - TABLE 1HH. Syphilis, Congenital to Syphilis, Primary and Secondary – 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island.

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
 Max: Maximum — Maximum case count during the previous 52 weeks.
  * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
Pooling, meta-analysis, and the evaluation of drug safety

Background
          The "integrated safety report" of the drug registration files submitted to health authorities usually summarizes the rates of adverse events observed for a new drug, placebo or active control drugs by pooling the safety data across the trials. Pooling consists of adding the numbers of events observed in a given treatment group across the trials and dividing the results by the total number of patients included in this group. Because it considers treatment groups rather than studies, pooling ignores validity of the comparisons and is subject to a particular kind of bias, termed "Simpson's paradox." In contrast, meta-analysis and other stratified analyses are less susceptible to bias.
        
        
          Methods
          We use a hypothetical, but not atypical, application to demonstrate that the results of a meta-analysis can differ greatly from those obtained by pooling the same data. In our hypothetical model, a new drug is compared to 1) a placebo in 4 relatively small trials in patients at high risk for a certain adverse event and 2) an active reference drug in 2 larger trials of patients at low risk for this event.
        
        
          Results
          Using meta-analysis, the relative risk of experiencing the adverse event with the new drug was 1.78 (95% confidence interval [1.02; 3.12]) compared to placebo and 2.20 [0.76; 6.32] compared to active control. By pooling the data, the results were, respectively, 1.00 [0.59; 1.70] and 5.20 [2.07; 13.08].
        
        
          Conclusions
          Because these findings could mislead health authorities and doctors, regulatory agencies should require meta-analyses or stratified analyses of safety data in drug registration files.
Strengthening Families 201: Sustaining and Deepening State Strengthening Families Efforts

This webinar was primarily for those states that have incorporated Strengthening Families as part of their child abuse and neglect prevention efforts. Strengthening Families is a strategy for engaging early care and education providers and others working with families with young children in building protective factors that have been shown by research to be connected to child abuse and neglect prevention. The webinar included discussion of new resources; new tools and new directions that can help states sustain and deepen their existing Strengthening Families work.

Presenter: Nilofer Ahsan, Center for the Study of Social Policy

View Webinar (WMV - 46 MB)

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 530099: 2-Chlorophenyl 6-bromohexanoate

Chemical compound data from PubChem database. IUPAC Name: 1,9-dimethyl-2-trimethylsilyloxypurin-6-one. Molecular Formula: C10H16N4O2Si. Molecular Weight: 252.34. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Somatropin

Humatrope is a prescription injectable medication containing somatropin, a synthetic form of human growth hormone, manufactured by Eli Lilly and Company. It comes in various strengths (e.g., 2mg, 5mg, 6mg, 12mg, 24mg vials) and is administered intramuscularly or subcutaneously to treat growth hormone deficiencies. Some formulations are discontinued. This information was generated using AI and is provided for informational and research purposes only.
2011 CMHS Uniform Reporting System (URS) Output Tables for West Virginia

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2011. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Weekly Influenza Vaccination Coverage and Intent for Vaccination, Overall, by Selected Demographics and Jurisdiction, Among Adults 18 Years and Older

• Weekly Influenza Vaccination Coverage and intent among adults 18 Years and Older by Demographic Characteristics and Jurisdiction 

 • Weekly estimates of influenza vaccination coverage and intent for vaccination among adults 18 years and older are calculated using data from the National Immunization Survey–Adult COVID Module (NIS–ACM) (https://www.cdc.gov/nis/about/index.html).
Systematic assessment of the quality of osteoporosis guidelines

Background
          Numerous agencies have developed clinical practice guidelines for the management of postmenopausal osteoporosis. The study objective was to conduct a systematic assessment of the quality of osteoporosis guidelines produced since 1998.
        
        
          Methods
          Guidelines were identified by searching MEDLINE (1998+), the world wide web, known guideline developer websites, bibliographies of retrieved guidelines, and through consultation with content experts. Each guideline was then assessed by three independent appraisers using the 'Appraisal Instrument for Clinical Guidelines' (version 1) by Cluzeau.
        
        
          Results
          We identified 26 unique guidelines from 1998–2001 and 21 met our inclusion criteria. Of the 21 guidelines reviewed, 8 were developed by medical societies, 6 by national groups, 6 by government agencies, and 1 by an international group. Twelve of the guidelines were published, 7 were organizational reports, and 2 were accessible only from the web. Half or more of the 20 items assessing the rigor of guideline development were met by 15% (median quality score 23%, range 5–80%, (95% CI 16.5, 34.7)), 81% met at least half of the 12 items assessing guideline content and context (median score 58%, range 17–83%, (95% CI 50.8, 65.5)), and none met half or more of the items assessing guideline application (median score 0%, range 0–47%, (95% CI -0.5 to 12.6)). Eight guidelines described the method used to assess the strength of evidence, and in 6 there was an explicit link between recommendations and the supporting evidence. Ten guidelines were judged not suitable for use in practice, 10 were acceptable with modification, and one was acceptable for use without modification.
        
        
          Conclusion
          The methodological quality of current osteoporosis guidelines is low, although their scores for clinical content were higher. Virtually no guidelines covered dissemination issues. Few guidelines were judged as acceptable for use in their current format.
Compound 526166: Diethyl 4-bromophenyl phosphate

Chemical compound data from PubChem database. IUPAC Name: (4-bromophenyl) diethyl phosphate. Molecular Formula: C10H14BrO4P. Molecular Weight: 309.09. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Interactions of pathogens and irritant chemicals in land-applied sewage sludges (biosolids)

Background
          Fertilisation of land with processed sewage sludges, which often contain low levels of pathogens, endotoxins, and trace amounts of industrial and household chemicals, has become common practice in Western Europe, the US, and Canada. Local governments, however, are increasingly restricting or banning the practice in response to residents reporting adverse health effects. These self-reported illnesses have not been studied and methods for assessing exposures of residential communities to contaminants from processed sewage sludges need to be developed.
        
        
          Methods
          To describe and document adverse effects reported by residents, 48 individuals at ten sites in the US and Canada were questioned about their environmental exposures and symptoms. Information was obtained on five additional cases where an outbreak of staphylococcal infections occurred near a land application site in Robesonia, PA. Medical records were reviewed in cases involving hospitalisation or other medical treatment. Since most complaints were associated with airborne contaminants, an air dispersion model was used as a means for potentially ruling out exposure to sludge as the cause of adverse effects.
        
        
          Results
          Affected residents lived within approximately 1 km of land application sites and generally complained of irritation (e.g., skin rashes and burning of the eyes, throat, and lungs) after exposure to winds blowing from treated fields. A prevalence of Staphylococcus aureus infections of the skin and respiratory tract was found. Approximately 1 in 4 of 54 individuals were infected, including 2 mortalities (septicaemia, pneumonia). This result was consistent with the prevalence of S. aureus infections accompanying diaper rashes in which the organism, which is commonly found in the lower human colon, tends to invade irritated or inflamed tissue.
        
        
          Conclusions
          When assessing public health risks from applying sewage sludges in residential areas, potential interactions of chemical contaminants with low levels of pathogens should be considered. An increased risk of infection may occur when allergic and non-allergic reactions to endotoxins and other chemical components irritate skin and mucus membranes and thereby compromise normal barriers to infection.
Patent AT-E401262-T1: [Translated] DEVICE FOR DISPENSING A FLUID FROM A CAVITY OF A CONTAINER

Disclosed is a device for dispensing a fluid, in particular a carbonated beverage, from a storage chamber of a container towards the outside via at least one closeable discharge port, comprising a pressure reservoir which is separated from the storage chamber and in which a pressurized propellant is accommodated, and which can be connected to the storage chamber via a pressure regulation mechanism. The pressure regulation mechanism includes an axially moveable regulating element that is impinged upon by means of a spring in the direction of an open position in which propellant is discharged from the pressure reservoir into the storage chamber. The ambient pressure to which the container is exposed acts upon the regulating element in the direction of the open position, and the internal pressure inside the storage chamber of the container acts upon the regulating element in the direction of the closed position.
Compound 529759: 4,6-Dimethyl-1,2,5-trithiepane

Chemical compound data from PubChem database. IUPAC Name: 4,6-dimethyl-1,2,5-trithiepane. Molecular Formula: C6H12S3. Molecular Weight: 180.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401801-T1: [Translated] METHOD FOR PRODUCING ANTIOXIDANTS FROM CURRY LEAVES (MURRAYA KOENIGII SPRENG.)

The present invention relates to a simple process for the preparation of safe, environmental friendly, and natural antioxidant conserve of activity ranging between 80-85%, comprising oleoresin from Indian curry leaves (Murraya Koenigii Spreng.), said process-comprising steps of drying the washed curry leaves at temperature ranging between 30-80° C., for time duration ranging between 2-10 hours, powdering the dried leaves into coarse powder form, extracting the powder with polar solvent preferably ketone with alkyl group, and obtaining antioxidant conserve comprising oleoresin from the extract by removing the solvent; also, use of antioxidant conserve at concentration ranging between ranging between 0.2 to 3.0%, comprising oleoresin from Indian curry leaves (Murraya Koenigii Spreng.) as an anti-oxidant in food and pharmaceutical substances and additives.
National Directory of Drug and Alcohol Abuse Treatment Facilities 2006

The National Directory of Drug and Alcohol Abuse Treatment Programs 2006 lists federal, state, local, and private facilities that provide substance abuse treatment services. The directory includes treatment facilities that are licensed, certified, or otherwise approved for inclusion in the directory by their state substance abuse agencies and that responded to the 2005 National Survey of Substance Abuse Treatment Services (N-SSATS). The information about each facility that appears in this directory was provided by that facility in response to the 2005 N-SSATS. The Substance Abuse and Mental Health Services Administration (SAMHSA) conducts the N-SSATS annually.
Compound 525627: N,N-Dimethyl-N'-heptyl-p-chlorobenzamidine

Chemical compound data from PubChem database. IUPAC Name: 4-chloro-N'-heptyl-N,N-dimethylbenzenecarboximidamide. Molecular Formula: C16H25ClN2. Molecular Weight: 280.83. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399794-T1: [Translated] MODIFIED GRANULOCYTE STIMULATING FACTOR (G-CSF) WITH REDUCED IMMUNOGENICITY

A method of preparing a modified granulocyte colony stimulating factor (G-CSF) protein having reduced immunogenicity relative to human G-CSF comprises the steps of (i) identifying one or more potential T-cell epitopes within the amino acid sequence of human G-CSF (SEQ ID NO: 1 ); (ii) designing at least one sequence variant of at least one potential T-cell epitope identified in step (i), wherein the sequence variant eliminates or substantially reduces the MHC class II binding activity of the potential T-cell epitope; (iii) preparing, by recombinant DNA techniques, at least one modified G-CSF protein including a sequence variant designed in step (ii); (iv) evaluating at least one modified G-CSF protein prepared in step (iii) for G-CSF activity and immunogenicity; and (v) selecting a modified G-CSF protein evaluated in step (iv) that has substantially the same therapeutic G-CSF biological activity as, but substantially less immunogenicity than, human G-CSF.
Compound 527243: (7,7-Dimethyl-6-methylidene-2-tricyclo[6.2.1.01,5]undecanyl)methyl acetate

Chemical compound data from PubChem database. IUPAC Name: (7,7-dimethyl-6-methylidene-2-tricyclo[6.2.1.01,5]undecanyl)methyl acetate. Molecular Formula: C17H26O2. Molecular Weight: 262.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.